Review Note
Last Update: 02/05/2025 08:20 AM
Current Deck: BPT QC
Published
Fields:
Front
A patient with congestive cardiac failure with an ejection fraction of 35% is referred for medical optimization. He is already on stable B-blocker therapy (carvediolol 25mg BD), there is no pulmonary congestion on examination, and he has NYHA Class II symptoms. He is not currently taking ACE-inhibitor therapy due to chronic cough. What is the next best therapy to commence to optimize his management?
A. Atorvastatin
B. Candesartan
C. Digoxin
D. Frusemide
E. Spironolactone
Back
B. Candesartan
-------------------------------------------------------------------
E. Spironolactone - should only be given in the absence of a contraindication. Monitor for renal function and potassium
Tags:
Suggested Changes:
Deck Changes (Suggestion to move the Note to the following Deck):
Field Changes:
Tag Changes: